Jan Janusz Sniatecki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jan Janusz Sniatecki has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Evgeny Goloborodko
Johannes Gutenberg University Mainz
5 shared publications- Adrian Gericke
Department of Ophthalmology, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany
4 shared publications Norbert Pfeiffer
Johannes Gutenberg University Mainz
4 shared publications- Andreas Patzak
Institute of Translational Physiology Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
3 shared publications Andreas Steege
University Medical Center Regensburg
3 shared publicationsFranz H. Grus
Johannes Gutenberg University Mainz
2 shared publications
Latest Publications
- Open Access
- 12 April 2024
- Published by BMJ
- Vol. 9 (Suppl 2) , A6.1-A6
P-15 Changing indications for penetrating keratoplasty and 5-years survival outcomes – a single tertiary centre experience
Purpose To investigate long-term graft survival rates of penetrating keratoplasties, patient characteristics and co-morbidities in a single tertiary care centre on the South Coast. Methods Retrospective, non-comparative case series review of 5-year follow-up for patients who underwent penetrating keratoplasty between 2008 and 2018. The primary outcome measures were 5-year corneal graft survival, graft surgery indications, and co-morbidities identification. Results 198 penetrating keratoplasties were performed, of which 32 were excluded from further investigation because of insufficient follow-up data. 60 (36%) grafts in 45 patients did not survive a 5-year follow-up. In this group, the mean age of transplant recipients was 64 years (range 18–90, median 67), with a male-to-female ratio of 5:4. 27 (45%) were re-graft surgeries, and 10 (17%) had more than three penetrating keratoplasties. The failure group often included more than one indication for surgery. Of these, the most prevalent were infective/therapeutic grounds (52%), bullous keratopathy (20%), herpes simplex keratitis (10%), corneal ectasia (8%) and trauma-related (5%). The most common co-morbidities in the graft failure group were glaucoma (47%), infectious keratitis (42%), glaucoma surgery (20%), anterior chamber intraocular lens (13%) and retinal detachment surgery (13%). Most patients in the failure group (78%) were of advanced age of more than 65 years old. Conclusions It was found that most penetrating keratoplasties failed due to infective keratitis. Patients in our graft failure group had high rates of ocular and medical co-morbidities, requiring multiple procedures and multidisciplinary care from various ophthalmic and medical subspecialties.
- 12 April 2024
- Published by BMJ
- Vol. 9 (Suppl 2) , A6.1-A6
Open AccessP-15 Changing indications for penetrating keratoplasty and 5-years survival outcomes – a single tertiary centre experience
Purpose To investigate long-term graft survival rates of penetrating keratoplasties, patient characteristics and co-morbidities in a single tertiary care centre on the South Coast. Methods Retrospective, non-comparative case series review of 5-year follow-up for patients who underwent penetrating keratoplasty between 2008 and 2018. The primary outcome measures were 5-year corneal graft survival, graft surgery indications, and co-morbidities identification. Results 198 penetrating keratoplasties were performed, of which 32 were excluded from further investigation because of insufficient follow-up data. 60 (36%) grafts in 45 patients did not survive a 5-year follow-up. In this group, the mean age of transplant recipients was 64 years (range 18–90, median 67), with a male-to-female ratio of 5:4. 27 (45%) were re-graft surgeries, and 10 (17%) had more than three penetrating keratoplasties. The failure group often included more than one indication for surgery. Of these, the most prevalent were infective/therapeutic grounds (52%), bullous keratopathy (20%), herpes simplex keratitis (10%), corneal ectasia (8%) and trauma-related (5%). The most common co-morbidities in the graft failure group were glaucoma (47%), infectious keratitis (42%), glaucoma surgery (20%), anterior chamber intraocular lens (13%) and retinal detachment surgery (13%). Most patients in the failure group (78%) were of advanced age of more than 65 years old. Conclusions It was found that most penetrating keratoplasties failed due to infective keratitis. Patients in our graft failure group had high rates of ocular and medical co-morbidities, requiring multiple procedures and multidisciplinary care from various ophthalmic and medical subspecialties.
- 9 December 2019
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 31 (2) , 643-648
Treatment of submacular hemorrhage with tissue plasminogen activator and pneumatic displacement in age-related macular degeneration
Purpose: To evaluate visual and anatomic outcomes following pars plana vitrectomy and intravitreal or subretinal tissue plasminogen activator for submacular hemorrhage in patients with age-related macular degeneration. Methods: This was a retrospective study on patients with a minimum follow-up of 12 months undertaken at a tertiary referral center. Data collected include demographic details, visual and optical coherence tomography changes, surgical details, and complications. Surgical results were compared with patients who were age and lesion size matched and treated with anti-vascular endothelial growth factor injections alone. Results: There were 36 patients in surgical and 18 patients in control group. Patients in surgical arm had pars plana vitrectomy, intravitreal tissue plasminogen activator with air 24 (67%), 6 (16%) with C3F8 gas, 1 (3%) with SF6 gas, 4 (11%) subretinal tissue plasminogen activator with air, and 1 (3%) with C2F6 as post-operative tamponade. Mean LogMAR in tissue plasminogen activator group at baseline was 1.56, and it was improved at all time points 1.06 at 1 month (p < 0.05), 0.91 at 6 months (p < 0.05), and 1.07 at 1 year (p < 0.05). Mean best corrected visual acuity in control group at baseline was 1.22LogMAR with no significant improvement at any time points: 1 month (1.27), 6 months (1.35), and 12 months (1.36). Complications included retinal detachment 5%, vitreous hemorrhage 7.5%, and cataract 19%. Conclusion: Pars plana vitrectomy with intravitreal (or subretinal) tissue plasminogen activator and pneumatic displacement can offer better outcome in comparison to anti-vascular endothelial growth factor alone in patients with submacular hemorrhage secondary to age-related macular degeneration.
- 9 December 2019
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 31 (2) , 643-648
Treatment of submacular hemorrhage with tissue plasminogen activator and pneumatic displacement in age-related macular degeneration
Purpose: To evaluate visual and anatomic outcomes following pars plana vitrectomy and intravitreal or subretinal tissue plasminogen activator for submacular hemorrhage in patients with age-related macular degeneration. Methods: This was a retrospective study on patients with a minimum follow-up of 12 months undertaken at a tertiary referral center. Data collected include demographic details, visual and optical coherence tomography changes, surgical details, and complications. Surgical results were compared with patients who were age and lesion size matched and treated with anti-vascular endothelial growth factor injections alone. Results: There were 36 patients in surgical and 18 patients in control group. Patients in surgical arm had pars plana vitrectomy, intravitreal tissue plasminogen activator with air 24 (67%), 6 (16%) with C3F8 gas, 1 (3%) with SF6 gas, 4 (11%) subretinal tissue plasminogen activator with air, and 1 (3%) with C2F6 as post-operative tamponade. Mean LogMAR in tissue plasminogen activator group at baseline was 1.56, and it was improved at all time points 1.06 at 1 month (p < 0.05), 0.91 at 6 months (p < 0.05), and 1.07 at 1 year (p < 0.05). Mean best corrected visual acuity in control group at baseline was 1.22LogMAR with no significant improvement at any time points: 1 month (1.27), 6 months (1.35), and 12 months (1.36). Complications included retinal detachment 5%, vitreous hemorrhage 7.5%, and cataract 19%. Conclusion: Pars plana vitrectomy with intravitreal (or subretinal) tissue plasminogen activator and pneumatic displacement can offer better outcome in comparison to anti-vascular endothelial growth factor alone in patients with submacular hemorrhage secondary to age-related macular degeneration.
- Open Access
- 1 September 2015
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 9, 1821-1827
Cataract surgery: factors influencing decision to treat and implications for training (south-east Scotland 2008–2014)
Purpose: To describe the population referred for cataract surgery, identify factors that influenced decision to treat, and patients suitable for ophthalmic training. Patients and methods: A total of 2,693 consecutive referrals over 6 years were interrogated using Business Objects software on cataract electronic patient records. Results: A total of 2,693 patients were referred for cataract surgery (group A). Of these patients 2,132 (79%) had surgery (group B) and 561 (21%) did not (group C). Age for group B vs group C: 672 (32%) vs 115 (20%) ≤69 years, PP=0.48; 586 (27%) vs 203 (36%) 80–89 years, PP=1.0. Visual acuity, group B vs group C: 556 (26%) vs 664 (59%) 6/12 or better; 1,275 (60%) vs 367 (33%) 6/18–6/60; 266 (12%) vs 64 (6%) counting fingers or worse, PPPP=0.87; COPD/asthma: 382 (17.9%) vs 93 (16.6%), P=0.53; heart disease: 535 (25.1%) vs 155 (27.6%), P=0.35; hypertension: 971 (45.5%) vs 263 (46.9%), P=0.73. Ocular history for group B vs C was significant (P Conclusion: We observed that surgery at a younger age with good levels of visual acuity was a factor in deferring cataract surgery. Cognitive impairment, cardiovascular accident, amblyopia, corneal and macular pathology significantly affected decision not to operate. We estimate that 80% of patients would be suitable for ophthalmic training.
- 1 September 2015
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 9, 1821-1827
Open AccessCataract surgery: factors influencing decision to treat and implications for training (south-east Scotland 2008–2014)
Purpose: To describe the population referred for cataract surgery, identify factors that influenced decision to treat, and patients suitable for ophthalmic training. Patients and methods: A total of 2,693 consecutive referrals over 6 years were interrogated using Business Objects software on cataract electronic patient records. Results: A total of 2,693 patients were referred for cataract surgery (group A). Of these patients 2,132 (79%) had surgery (group B) and 561 (21%) did not (group C). Age for group B vs group C: 672 (32%) vs 115 (20%) ≤69 years, PP=0.48; 586 (27%) vs 203 (36%) 80–89 years, PP=1.0. Visual acuity, group B vs group C: 556 (26%) vs 664 (59%) 6/12 or better; 1,275 (60%) vs 367 (33%) 6/18–6/60; 266 (12%) vs 64 (6%) counting fingers or worse, PPPP=0.87; COPD/asthma: 382 (17.9%) vs 93 (16.6%), P=0.53; heart disease: 535 (25.1%) vs 155 (27.6%), P=0.35; hypertension: 971 (45.5%) vs 263 (46.9%), P=0.73. Ocular history for group B vs C was significant (P Conclusion: We observed that surgery at a younger age with good levels of visual acuity was a factor in deferring cataract surgery. Cognitive impairment, cardiovascular accident, amblyopia, corneal and macular pathology significantly affected decision not to operate. We estimate that 80% of patients would be suitable for ophthalmic training.
- 28 February 2015
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 56 (2) , 472-479
Effect of the M1 Muscarinic Acetylcholine Receptor on Retinal Neuron Number Studied with Gene-Targeted Mice
Pharmacological activation of the M1 muscarinic receptor subtype was suggested to promote the survival of retinal neurons. We examined the hypothesis that the M1 receptor is crucial for retinal neuron survival in vivo by using mice devoid of the M1 receptor gene. Muscarinic receptor gene expression was determined in the retina using real-time PCR. The amount of neurons in the retinal ganglion cell layer and of axons in the optic nerve was determined in retinal wholemounts stained with cresyl blue and in optic nerve cross-sections stained with toluidine blue, respectively. mRNA of all five muscarinic receptor subtypes (M1–M5) was detected in the retina from wild-type mice. Remarkably, M2 and M3 receptor mRNA were most abundant. In retinas from M1 receptor-deficient mice, M4 receptor mRNA expression was increased compared to that of wild-type mice, while no marked changes in the mRNA expression levels of the other muscarinic receptor subtypes were observed. The amount of cells in the retinal ganglion cell layer and the amount of axons in the optic nerve did not differ between M1 receptor-deficient and wild-type mice. The present findings suggest that the M1 receptor is not essential for the survival of retinal neurons in vivo.
- 28 February 2015
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 56 (2) , 472-479
Effect of the M1 Muscarinic Acetylcholine Receptor on Retinal Neuron Number Studied with Gene-Targeted Mice
Pharmacological activation of the M1 muscarinic receptor subtype was suggested to promote the survival of retinal neurons. We examined the hypothesis that the M1 receptor is crucial for retinal neuron survival in vivo by using mice devoid of the M1 receptor gene. Muscarinic receptor gene expression was determined in the retina using real-time PCR. The amount of neurons in the retinal ganglion cell layer and of axons in the optic nerve was determined in retinal wholemounts stained with cresyl blue and in optic nerve cross-sections stained with toluidine blue, respectively. mRNA of all five muscarinic receptor subtypes (M1–M5) was detected in the retina from wild-type mice. Remarkably, M2 and M3 receptor mRNA were most abundant. In retinas from M1 receptor-deficient mice, M4 receptor mRNA expression was increased compared to that of wild-type mice, while no marked changes in the mRNA expression levels of the other muscarinic receptor subtypes were observed. The amount of cells in the retinal ganglion cell layer and the amount of axons in the optic nerve did not differ between M1 receptor-deficient and wild-type mice. The present findings suggest that the M1 receptor is not essential for the survival of retinal neurons in vivo.
- 1 October 2014
- Published by Elsevier in Experimental Eye Research
- Vol. 127, 1-8
Role of nitric oxide synthase isoforms for ophthalmic artery reactivity in mice
- 1 October 2014
- Published by Elsevier in Experimental Eye Research
- Vol. 127, 1-8
Role of nitric oxide synthase isoforms for ophthalmic artery reactivity in mice
- 1 April 2013
- Published by Elsevier in Experimental Eye Research
- Vol. 109, 60-66
Contribution of nitric oxide synthase isoforms to cholinergic vasodilation in murine retinal arterioles
- 1 April 2013
- Published by Elsevier in Experimental Eye Research
- Vol. 109, 60-66
Contribution of nitric oxide synthase isoforms to cholinergic vasodilation in murine retinal arterioles
- Open Access
- 1 September 2011
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 52 (10) , 7479-7484
Identification of the Muscarinic Acetylcholine Receptor Subtype Mediating Cholinergic Vasodilation in Murine Retinal Arterioles
Purpose.: To identify the muscarinic acetylcholine receptor subtype that mediates cholinergic vasodilation in murine retinal arterioles. Methods.: Muscarinic receptor gene expression was determined in murine retinal arterioles using real-time PCR. To assess the functional relevance of muscarinic receptors for mediating vascular responses, retinal vascular preparations from muscarinic receptor–deficient mice were studied in vitro. Changes in luminal arteriole diameter in response to muscarinic and nonmuscarinic vasoactive substances were measured by video microscopy. Results.: Only mRNA for the M3 receptor was detected in retinal arterioles. Thus, M3 receptor–deficient mice (M3R−/−) and respective wild-type controls were used for functional studies. Acetylcholine concentration-dependently dilated retinal arterioles from wild-type mice. In contrast, vasodilation to acetylcholine was almost completely abolished in retinal arterioles from M3R−/− mice, whereas responses to the nitric oxide (NO) donor nitroprusside were retained. Carbachol, an acetylcholinesterase-resistant analog of acetylcholine, also evoked dilation in retinal arterioles from wild-type, but not from M3R−/−, mice. Vasodilation responses from wild-type mice to acetylcholine were negligible after incubation with the non–subtype-selective muscarinic receptor blocker atropine or the NO synthase inhibitor Nω-nitro-l-arginine methyl ester, and were even reversed to contraction after endothelial damage with 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate. Conclusions.: These findings provide evidence that endothelial M3 receptors mediate cholinergic vasodilation in murine retinal arterioles via activation of NO synthase.
- 1 September 2011
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 52 (10) , 7479-7484
Open AccessIdentification of the Muscarinic Acetylcholine Receptor Subtype Mediating Cholinergic Vasodilation in Murine Retinal Arterioles
Purpose.: To identify the muscarinic acetylcholine receptor subtype that mediates cholinergic vasodilation in murine retinal arterioles. Methods.: Muscarinic receptor gene expression was determined in murine retinal arterioles using real-time PCR. To assess the functional relevance of muscarinic receptors for mediating vascular responses, retinal vascular preparations from muscarinic receptor–deficient mice were studied in vitro. Changes in luminal arteriole diameter in response to muscarinic and nonmuscarinic vasoactive substances were measured by video microscopy. Results.: Only mRNA for the M3 receptor was detected in retinal arterioles. Thus, M3 receptor–deficient mice (M3R−/−) and respective wild-type controls were used for functional studies. Acetylcholine concentration-dependently dilated retinal arterioles from wild-type mice. In contrast, vasodilation to acetylcholine was almost completely abolished in retinal arterioles from M3R−/− mice, whereas responses to the nitric oxide (NO) donor nitroprusside were retained. Carbachol, an acetylcholinesterase-resistant analog of acetylcholine, also evoked dilation in retinal arterioles from wild-type, but not from M3R−/−, mice. Vasodilation responses from wild-type mice to acetylcholine were negligible after incubation with the non–subtype-selective muscarinic receptor blocker atropine or the NO synthase inhibitor Nω-nitro-l-arginine methyl ester, and were even reversed to contraction after endothelial damage with 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate. Conclusions.: These findings provide evidence that endothelial M3 receptors mediate cholinergic vasodilation in murine retinal arterioles via activation of NO synthase.
- 1 May 2011
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 300 (5) , H1602-H1608
Role of M1, M3, and M5muscarinic acetylcholine receptors in cholinergic dilation of small arteries studied with gene-targeted mice
Acetylcholine regulates perfusion of numerous organs via changes in local blood flow involving muscarinic receptor-induced release of vasorelaxing agents from the endothelium. The purpose of the present study was to determine the role of M1, M3, and M5muscarinic acetylcholine receptors in vasodilation of small arteries using gene-targeted mice deficient in either of the three receptor subtypes (M1R−/−, M3R−/−, or M5R−/−mice, respectively). Muscarinic receptor gene expression was determined in murine cutaneous, skeletal muscle, and renal interlobar arteries using real-time PCR. Moreover, respective arteries from M1R−/−, M3R−/−, M5R−/−, and wild-type mice were isolated, cannulated with micropipettes, and pressurized. Luminal diameter was measured using video microscopy. mRNA for all five muscarinic receptor subtypes was detected in all three vascular preparations from wild-type mice. However, M3receptor mRNA was found to be most abundant. Acetylcholine produced dose-dependent dilation in all three vascular preparations from M1R−/−, M5R−/−, and wild-type mice. In contrast, cholinergic dilation was virtually abolished in arteries from M3R−/−mice. Deletion of either M1, M3, or M5receptor genes did not affect responses to nonmuscarinic vasodilators, such as substance P and nitroprusside. These findings provide the first direct evidence that M3receptors mediate cholinergic vasodilation in cutaneous, skeletal muscle, and renal interlobar arteries. In contrast, neither M1nor M5receptors appear to be involved in cholinergic responses of the three vascular preparations tested.
- 1 May 2011
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 300 (5) , H1602-H1608
Role of M1, M3, and M5muscarinic acetylcholine receptors in cholinergic dilation of small arteries studied with gene-targeted mice
Acetylcholine regulates perfusion of numerous organs via changes in local blood flow involving muscarinic receptor-induced release of vasorelaxing agents from the endothelium. The purpose of the present study was to determine the role of M1, M3, and M5muscarinic acetylcholine receptors in vasodilation of small arteries using gene-targeted mice deficient in either of the three receptor subtypes (M1R−/−, M3R−/−, or M5R−/−mice, respectively). Muscarinic receptor gene expression was determined in murine cutaneous, skeletal muscle, and renal interlobar arteries using real-time PCR. Moreover, respective arteries from M1R−/−, M3R−/−, M5R−/−, and wild-type mice were isolated, cannulated with micropipettes, and pressurized. Luminal diameter was measured using video microscopy. mRNA for all five muscarinic receptor subtypes was detected in all three vascular preparations from wild-type mice. However, M3receptor mRNA was found to be most abundant. Acetylcholine produced dose-dependent dilation in all three vascular preparations from M1R−/−, M5R−/−, and wild-type mice. In contrast, cholinergic dilation was virtually abolished in arteries from M3R−/−mice. Deletion of either M1, M3, or M5receptor genes did not affect responses to nonmuscarinic vasodilators, such as substance P and nitroprusside. These findings provide the first direct evidence that M3receptors mediate cholinergic vasodilation in cutaneous, skeletal muscle, and renal interlobar arteries. In contrast, neither M1nor M5receptors appear to be involved in cholinergic responses of the three vascular preparations tested.